How to Use Petrelintide
Complete guide to Petrelintide dosing, administration, timing, and protocol recommendations.
Quick Overview
Petrelintide is a long-acting amylin analog from Zealand Pharma, co-developed with Roche, designed as a once-weekly injection for obesity. The pitch is gentler weight loss than GLP-1 drugs but with far less nausea and vomiting. Two phase 2 trials read out positively in 2026 (up to 10.7% weight loss at 42 weeks), and a roughly 7,000-person phase 3 program has started. It is not approved anywhere.
Dosing Guidelines
Common Dose
Not publicly disclosed (once-weekly trial doses)
Frequency
Once weekly
Dose Range
Five weekly dose levels tested in phase 2; mg amounts not released in topline data
Note: Zealand and Roche have not published the specific mg doses from the phase 2 trials in their topline releases. Doses were escalated every fourth week. Any dose quoted online is not backed by published trial data.
Administration Method
Subcutaneous injection once weekly
Best Time to Take
Same day each week
Long-acting weekly analog designed for steady exposure, so the day matters more than the hour.
Protocol Duration
16 weeks (phase 1b) to 42 weeks (phase 2) in completed trials
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Nausea (mostly mild, mainly during dose escalation)
- •Diarrhea and constipation at rates similar to placebo in phase 2
- •Vomiting uncommon (none at the maximally effective dose in ZUPREME-1)
- •Reduced appetite
- •No long-term human safety data
Frequently Asked Questions
What is the recommended dose for Petrelintide?
Not publicly disclosed (once-weekly trial doses)
How do you administer Petrelintide?
Subcutaneous injection once weekly
When is the best time to take Petrelintide?
Same day each week
How long should you use Petrelintide?
16 weeks (phase 1b) to 42 weeks (phase 2) in completed trials
This information is for educational purposes only. Always consult with a healthcare professional before using any peptide. Dosing information is based on research literature and community reports, not medical advice.